Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

INTRODUCTION: The main objective of this work was to assess the maintenance of effectiveness of subcutaneous tocilizumab 6 months after switching from intravenous to subcutaneous formulation in patients with rheumatoid arthritis (RA) in a real-world setting. Secondary objectives aimed to describe th...

Descripción completa

Detalles Bibliográficos
Autores principales: Darloy, Jean, Segaud, Nicolas, Salmon, Jean-Hugues, Eschard, Jean-Paul, Goëb, Vincent, Deprez, Xavier, Guyot, Marie-Hélène, Houvenagel, Eric, Lecuyer, Nicolas, Marguerie, Laurent, Gally, Samuel, Pau, David, Idier, Isabelle, Baudens, Guy, Flipo, René-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393270/
https://www.ncbi.nlm.nih.gov/pubmed/30632015
http://dx.doi.org/10.1007/s40744-018-0138-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393270/
https://www.ncbi.nlm.nih.gov/pubmed/30632015
http://dx.doi.org/10.1007/s40744-018-0138-y

Ejemplares similares